FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024982013> ?p ?o ?g. }

• W2024982013 endingPage "1212" @default.
• W2024982013 startingPage "1210" @default.
• W2024982013 abstract "No AccessJournal of UrologyReflux1 Sep 1997Gax 65: A New Injectable Cross-Linked Collagen for the Endoscopic Treatment of Vesicoureteral Reflux-A Double-Blind Study Evaluating Its Efficiency in Children P. Frey, F. Gudinchet, and P. Jenny P. FreyP. Frey More articles by this author , F. GudinchetF. Gudinchet More articles by this author , and P. JennyP. Jenny More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)64431-8AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: In the experimental model glutaraldehyde cross-linked collagen GAX 65 * with a collagen concentration of 65 mg./ml. has proved to have more persistent implant volume and, therefore, a better antireflux effect than GAX 35,* which is injected more commonly. The aim of this study was to evaluate the potential clinical application of GAX 65. Materials and Methods: Ten boys and 8 girls an average of 4.6 years old presented with unilateral or bilateral primary reflux and were randomly divided into 2 groups. All refluxing ureters received 1 endoscopic subureteral injection of an average of approximately 2.9 ml. collagen. In group 1, 16 refluxing ureters were treated with GAX 65 and in group 2, 12 were treated with GAX 35. In all patients voiding cystourethrography was performed immediately after injection and 3 months postoperatively, and ultrasound was done on day 1, and at 1 and 3 months. Implant volume was calculated at the day of injection and at 3 months. The distribution of reflux grades was comparable in the 2 groups. Results: Both materials had excellent injection properties. Immediately after injection all ureters were reflux-free. Of the 16 ureters treated with GAX 65 14 (87.5%) were reflux-free at the 3-month followup. Three months postoperatively ultrasound revealed an average implant volume increase of one-third. However, of the 12 ureters treated with GAX 35 reflux had resolved in 59.3% and the average implant volume had decreased by half 3 months after injection. Conclusions: Three months after endoscopic subureteral injection of GAX 65 vesicoureteral reflux was absent in 87.5% of patients. Therefore, GAX 65 has greater potential for treating reflux in the short term than GAX 35. To define the final efficacy of GAX 65 for treating vesicoureteral reflux, long-term evaluation of this series is necessary. In addition, further studies are mandatory to prove the long-term advantage of this new injectable substance. References 1 : Die endoskopische Behandlung des vesikoureterorenalen. Refluxes beim Kind.. Urologe A1996; 35: 97. Google Scholar 2 : Endoscopic subureteral collagen injection for the treatment of vesicoureteral reflux in infants and children.. J. Urol.1995; 154: 804. Abstract, Google Scholar 3 : Limitations and alternatives to endoscopic correction of vesicoureteral reflux with Polytef paste.. Ped. Surg. Int.1989; 4: 149. Google Scholar 4 : Traitement endoscopique du reflux vesicorenal chez l'enfant.. Arch. Ped.1994; 1: 93. Google Scholar 5 : Endoscopic treatment of vesicoureteral reflux with a chondrocyte-alginate suspension.. J. Urol.1994; 152: 641. part 2. Abstract, Google Scholar 6 : A new bioimplant for the treatment of vesicoureteral reflux.. Dial. Ped. Urol.1994; 17: 2. Google Scholar 7 : Subureteric lipoinjection for vesicoureteral reflux in renal transplant candidates.. Urology1994; 43: 174. Google Scholar 8 : Physical and histological behavior of a new injectable collagen (GAX 65) implanted into the submucosal space of the mini-pig bladder.. J. Urol.1995; 154: 812. part 2. Abstract, Google Scholar 9 : Subureteral collagen injection for the endoscopic treatment of vesicoureteral reflux in children. Followup study of 97 treated ureters and histological analysis of collagen implants.. J. Urol.1992; 148: 718. part 2. Abstract, Google Scholar From the Departments of Pediatric Surgery and Pediatric Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne and University Children's Hospital, Basel, Switzerland.© 1997 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byKIRSCH A, PEREZ-BRAYFIELD M and SCHERZ H (2018) Minimally Invasive Treatment of Vesicoureteral Reflux with Endoscopic Injection of Dextranomer/Hyaluronic Acid Copolymer: The Children’s Hospitals of Atlanta ExperienceJournal of Urology, VOL. 170, NO. 1, (211-215), Online publication date: 1-Jul-2003.HAFERKAMP A, MÖHRING K, STAEHLER G and DÖRSAM J (2018) PITFALLS OF REPEAT SUBURETERAL BOVINE COLLAGEN INJECTIONS FOR THE ENDOSCOPIC TREATMENT OF VESICOURETERAL REFLUXJournal of Urology, VOL. 163, NO. 6, (1919-1921), Online publication date: 1-Jun-2000.HAFERKAMP A, MÖHRING K, STAEHLER G, GERNER H and DÖRSAM J (2018) LONG-TERM EFFICACY OF SUBURETERAL COLLAGEN INJECTION FOR ENDOSCOPIC TREATMENT OF VESICOURETERAL REFLUX IN NEUROGENIC BLADDER CASESJournal of Urology, VOL. 163, NO. 1, (274-277), Online publication date: 1-Jan-2000. Volume 158Issue 3September 1997Page: 1210-1212 Advertisement Copyright & Permissions© 1997 by American Urological Association, Inc.MetricsAuthor Information P. Frey More articles by this author F. Gudinchet More articles by this author P. Jenny More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2024982013 created "2016-06-24" @default.
• W2024982013 creator A5005949087 @default.
• W2024982013 creator A5018100504 @default.
• W2024982013 creator A5022089139 @default.
• W2024982013 date "1997-09-01" @default.
• W2024982013 modified "2023-09-23" @default.
• W2024982013 title "Gax 65: A New Injectable Cross-Linked Collagen for the Endoscopic Treatment of Vesicoureteral Reflux-A Double-Blind Study Evaluating Its Efficiency in Children" @default.
• W2024982013 cites W113459969 @default.
• W2024982013 cites W1967061852 @default.
• W2024982013 cites W1968326453 @default.
• W2024982013 cites W2169898071 @default.
• W2024982013 cites W2417624657 @default.
• W2024982013 cites W4321059365 @default.
• W2024982013 doi "https://doi.org/10.1016/s0022-5347(01)64431-8" @default.
• W2024982013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9258175" @default.
• W2024982013 hasPublicationYear "1997" @default.
• W2024982013 type Work @default.
• W2024982013 sameAs 2024982013 @default.
• W2024982013 citedByCount "40" @default.
• W2024982013 countsByYear W20249820132015 @default.
• W2024982013 countsByYear W20249820132019 @default.
• W2024982013 countsByYear W20249820132021 @default.
• W2024982013 crossrefType "journal-article" @default.
• W2024982013 hasAuthorship W2024982013A5005949087 @default.
• W2024982013 hasAuthorship W2024982013A5018100504 @default.
• W2024982013 hasAuthorship W2024982013A5022089139 @default.
• W2024982013 hasConcept C126322002 @default.
• W2024982013 hasConcept C126838900 @default.
• W2024982013 hasConcept C126894567 @default.
• W2024982013 hasConcept C141071460 @default.
• W2024982013 hasConcept C142724271 @default.
• W2024982013 hasConcept C143753070 @default.
• W2024982013 hasConcept C204787440 @default.
• W2024982013 hasConcept C27081682 @default.
• W2024982013 hasConcept C2777609623 @default.
• W2024982013 hasConcept C2778802166 @default.
• W2024982013 hasConcept C2779134260 @default.
• W2024982013 hasConcept C2781411149 @default.
• W2024982013 hasConcept C2991744798 @default.
• W2024982013 hasConcept C43270747 @default.
• W2024982013 hasConcept C71924100 @default.
• W2024982013 hasConceptScore W2024982013C126322002 @default.
• W2024982013 hasConceptScore W2024982013C126838900 @default.
• W2024982013 hasConceptScore W2024982013C126894567 @default.
• W2024982013 hasConceptScore W2024982013C141071460 @default.
• W2024982013 hasConceptScore W2024982013C142724271 @default.
• W2024982013 hasConceptScore W2024982013C143753070 @default.
• W2024982013 hasConceptScore W2024982013C204787440 @default.
• W2024982013 hasConceptScore W2024982013C27081682 @default.
• W2024982013 hasConceptScore W2024982013C2777609623 @default.
• W2024982013 hasConceptScore W2024982013C2778802166 @default.
• W2024982013 hasConceptScore W2024982013C2779134260 @default.
• W2024982013 hasConceptScore W2024982013C2781411149 @default.
• W2024982013 hasConceptScore W2024982013C2991744798 @default.
• W2024982013 hasConceptScore W2024982013C43270747 @default.
• W2024982013 hasConceptScore W2024982013C71924100 @default.
• W2024982013 hasIssue "3" @default.
• W2024982013 hasLocation W20249820131 @default.
• W2024982013 hasLocation W20249820132 @default.
• W2024982013 hasOpenAccess W2024982013 @default.
• W2024982013 hasPrimaryLocation W20249820131 @default.
• W2024982013 hasRelatedWork W1988193249 @default.
• W2024982013 hasRelatedWork W1992510734 @default.
• W2024982013 hasRelatedWork W2003014396 @default.
• W2024982013 hasRelatedWork W2021844222 @default.
• W2024982013 hasRelatedWork W2071193357 @default.
• W2024982013 hasRelatedWork W2089801434 @default.
• W2024982013 hasRelatedWork W2161111787 @default.
• W2024982013 hasRelatedWork W2279662535 @default.
• W2024982013 hasRelatedWork W2989290002 @default.
• W2024982013 hasRelatedWork W4241354204 @default.
• W2024982013 hasVolume "158" @default.
• W2024982013 isParatext "false" @default.
• W2024982013 isRetracted "false" @default.
• W2024982013 magId "2024982013" @default.
• W2024982013 workType "article" @default.